

November 17, 2025

**To**

BSE Limited  
Corporate Relationship Department  
25th Floor, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001  
**BSE Scrip Code: 524743**

**To**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th floor  
Plot No. C/ 1, G Block,  
Bandra-Kurla Complex Bandra (E),  
Mumbai - 400 051  
**NSE Symbol: FISCHER**

Dear Sir,

**Reg : Press Release: Time Medical India Announces Breakthrough Low-Field TOF MRI for Aneurysm Screening with Dr. Iype Cherian**

We enclose a press release regarding **"Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of the Company announces New Low-Field TOF MRI Platform for Nationwide Aneurysm Screening, Developed in Collaboration with Dr. Iype Cherian"**, for dissemination.

Thanking you,  
Yours Truly,  
For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



**ARAVINDKUMAR V**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**





CIN L86900AP1993PLC118162

**Corporate Office** : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006  
**Registered Office** : No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyanadu Mandal, Visakhapatnam, 530032

**Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of the Company announces New Low-Field TOF MRI Platform for Nationwide Aneurysm Screening, Developed in Collaboration with Dr. Iype Cherian**

**Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of the Company today announced a major technological milestone with the introduction of VEGA, a heavily optimized permanent-magnet MRI system engineered specifically for rapid, non-contrast TOF angiographic screening of unruptured intracranial aneurysms.. The system has been engineered in close partnership with Dr. Iype Cherian, a leading neurosurgeon who has long advocated for population-level screening as India's most practical strategy to prevent aneurysm-related deaths.**


Unruptured intracranial aneurysms are far more common than most people realize. Global studies consistently show that about 3.2% of adults carry an aneurysm, and in the Indian population this translates to nearly 30 million people—a staggering number for a condition that can be detected non-invasively and treated safely before causing harm. Each year, an estimated 85,000 to 115,000 Indians suffer a subarachnoid haemorrhage, most often between the ages of 40 and 60, when individuals contribute most actively to their families and to the economy. When an aneurysm ruptures, the consequences are devastating: mortality reaches 26–45%, and including pre-hospital events, nearly half of all patients never make it to treatment. Those who survive frequently face long-term neurological disability.

India represents one of the world's largest untapped opportunities for neurovascular screening. Based on reliable demographic sources, the population above 40 years of age—the stage at which aneurysm risk begins to rise sharply—is estimated at well over 700 million people, forming one of the largest preventive-screening cohorts anywhere in the world. Even at a conservative aneurysm prevalence of 3%, this translates into a visible screening population of more than 21 million individuals. If we consider a planning ratio of 2 MRI scanners per million population, India would have the capacity to screen far more individuals proactively.

PRESENTED BY DR. IYPE CHERIAN

# ANEURYSM AWARENESS

A ruptured aneurysm resulting in a subarachnoid hemorrhage constitutes one of the most critical emergencies in the field of neurology.



**MORTALITY IS 26-45% AND NEARLY HALF NEVER MAKE IT TO THE HOSPITAL**

3.2% of adults have an unruptured UIA that means 30 million Indians carry a potential fatal vascular defect

Expanding access to affordable, low-field TOF MRI systems can help society shift from late detection to early intervention, improving outcomes for families and strengthening community brain health. In contrast, elective treatment of an unruptured aneurysm is remarkably safe, with modern clipping or coiling procedures carrying 0.5–2.5% mortality and offering patients an excellent chance of returning to full, productive lives. Countries like Japan, the United States, Korea, and several European nations have already shown that early identification changes outcomes dramatically. Japan's national "Brain Dock" program, for example, routinely detects aneurysms in healthy adults at rates around 4.3%, reducing the number of catastrophic ruptures and long-term disability. **Yet in India, early detection remains rare. Conventional tools such as CT angiography involve radiation and contrast, making them unsuitable for large-scale screening. High-field MRI systems, although excellent diagnostically, are expensive to operate, require helium, and are difficult to deploy outside major urban centres. As a result, most aneurysms in India are discovered only after they rupture.**

**This is where the new Time Medical India's system represents a transformative shift. By using a permanent-magnet low-field design, the scanner avoids helium entirely, consumes far less power, and requires minimal maintenance. Its optimized TOF sequence produces high-quality vascular imaging within six minutes, without radiation or contrast. This design makes it feasible to place the scanner in district hospitals, semi-urban clinics, and mobile diagnostic units—bringing aneurysm detection within reach of millions who currently have no access to preventive imaging.**

**Artificial intelligence plays a central role in scaling this vision. Modern deep-learning models can detect aneurysms on TOF scans with more than 95% sensitivity, allowing radiologists to supervise large volumes of studies through a hub-and-spoke teleradiology network. This ensures that screening can expand far beyond the limits of specialist manpower.**

This scanner has been designed for scale, sustainability, and accessibility, Time Medical said in a statement. It enables districts and smaller institutions to perform high-value neurovascular screening at a cost structure that was previously impossible.



## Quotes:

### **Dr. Iype Cherian, Neurosurgeon at Parul University, explained:**

Aneurysm rupture is one of the most catastrophic neurological events, yet it is entirely preventable when detected in time. Low-field MRI allows India to move from reacting to emergencies to preventing them altogether.

### **Ms. Svetlana, Director, Time Medical International Ventures (I) P Ltd:**

The introduction of VEGA—a fully optimized, ready-to-deploy low-field TOF MRI platform—marks a significant step forward in making preventive neurovascular screening accessible at scale. VEGA has been purpose-built to deliver rapid, contrast-free TOF vascular imaging, supported by a permanent-magnet design that eliminates helium dependence and significantly lowers operational costs. This combination of efficiency, affordability, and reliability makes VEGA ideally suited for deployment across district hospitals and semi-urban clinics. With VEGA, we are creating a pathway for earlier detection and proactive brain health, ensuring that communities everywhere can benefit from advanced neuro-imaging without the traditional barriers of cost and infrastructure.

## **About Dr. Iype Cherian**

**Dr. Iype Cherian** is a pioneering neurosurgeon, educator, and innovator whose distinguished career embodies surgical mastery, inventive spirit, and global impact. Having completed his **M.Ch (Neurosurgery)** at **CMC, Vellore**, and a **Fellowship in Skull Base and Vascular Neurosurgery** at **Nagoya**, Dr. Cherian has devoted his life to advancing the frontiers of neurosurgical science and education.

His groundbreaking contributions include the description of **Cisternostomy (2007)** and the concept of **Brain Cooling**, both of which have significantly influenced contemporary neurosurgical practice and postoperative recovery strategies. Renowned for "*Unlocking the Skull Base*," he developed and refined advanced microsurgical routes such as the **Transcavernous** and **Modified Kawase** approaches creating safer and more effective pathways to access complex intracranial regions.

As **General Counsellor of the Asian Congress of Neurological Surgeons (ACNS, 2021)**, Dr. Cherian is widely recognized as a global authority in **Ultra Micro Neurosurgery** and in the design of next-generation surgical instruments. His visionary approach led to the creation of the world's first **Exoscope – Sanma Yoko**, with which he has amassed one of the largest global experiences in Exoscope Surgery.





His inventive portfolio extends to the **STMC Bypass Set**, the **Medharanya Theatre Concept**, the **Sookshmaranga Endovascular Robot**, and **DRIS-iMRI**, all reflecting his deep commitment to precision, technological innovation, and patient-centered excellence.

Currently serving as **Director of Neuro Sciences at the Parul Institute of Medical Sciences & Research**, he continues to mentor surgeons worldwide as the **Founder and President of Neurosurgery Coach**, his global training initiative promoting advanced micro-neurosurgical skill development. He is also the **Counsellor General of the Asian Congress of Neurological Surgeons (ACNS)**.

His initiative, **Neurosurgery Coach**, stands as a premier platform for nurturing young neurosurgeons across the world, imparting critical micro-neurosurgical techniques and strategic surgical thinking. A true visionary in accessible healthcare, Dr. Cherian remains deeply mindful that the majority of the world's population resides in low- and middle-income countries where advanced neurosurgical infrastructure is limited. His mission is to empower surgeons from these regions to lead the next era of neurosurgical excellence—rooted in **compassion, innovation, and purpose**.

### **About Time Medical India**

Time Medical is an innovator in the medical diagnostic imaging industry aiming to bring advanced, accessible, and affordable imaging to all populations. With paradigm- shifting technologies, Time Medical developed advanced medical imaging systems and cost-effective service solutions to meet emerging global healthcare needs. Time Medical's manufacturing plant in Andhra Pradesh MedTech Zone (AMTZ) Vishakhapatnam, will focus on developing advance MRI systems for India.

For further information, please contact:

**Fischer Medical Ventures Limited**

Email: **enquiry@fischermv.com**

Website: **www.fischermv.com**

Contact: **9080966548**

### **Disclaimer:**

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.

\*\*\*